Trump reverses planned ban of flavored e-cigarettes

The Trump administration is walking back on its plan to ban flavored e-cigarettes amidst an epidemic of lung illnesses and deaths related to vaping.

The change of direction for the administration came after President Trump was swayed by advisors warning of political backlash about banning the products, The New York Times reported. Action on banning flavored vaping products, which are targeted toward young consumers, appears to have been set aside, according to the NY Times.  

More than 2,000 people have been confirmed across nearly all states to have the illness, known as e-cigarette, or vaping, product use associated lung injury (EVALI), and at least 39 deaths have been reported, according to the CDC. The agency has identified vitamin E acetate as the possible harmful additive in the vaping products, but the exact cause of EVALI is still unknown. Recent studies have indicated vaping could be just as harmful––or more harmful––than smoking traditional cigarettes.

Headlines about the public health crisis caused Trump to first announce a future ban on some vaping products, but e-cigarette loyalists decried that stance. Trump has decided to meet with more groups and stall making a policy decision.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

A string of executive orders from the White House created serious concerns among radiologists and other healthcare providers throughout the United States. The American College of Radiology issued a statement to help guide its members through the chaos. 

Bridgefield Capital, founded in 2015, has previously invested in such popular brands as Cirque Du Soleil, Del Monte and Quiksilver. This transaction is expected to be completed in the second half of 2025. 

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it.